- Home » News and Events
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings
Oct 21, 2024
Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today issued the following open letter to customers:
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
Oct 14, 2024
Catalent announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization (CDMO) with locations in Belgium, Spain, the Netherlands and Sweden.
Catalent Completes $25 Million Expansion of its Clinical Supply Facility in Schorndorf, Germany
Jul 16, 2024
Catalent today announced it has completed expansion of its clinical supply facility in Schorndorf, Germany.
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer
May 8, 2024
Catalent will provide process development and cGMP manufacturing of Siren Biotechnology’s AAV vector-based therapeutic candidates for use in clinical trials.
Catalent Publishes Fifth Annual Corporate Responsibility Report
Mar 7, 2024
The 2023 Corporate Responsibility Report highlights progress across every pillar of Catalent’s corporate responsibility strategy – People, Environment, and Community.
Novo Holdings to Acquire Catalent
Feb 5, 2024
Catalent and Novo Holdings have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.
Catalent Announces Addition of Potent Capsule Filling Capabilities for Inhaled Dry Powders at its Boston, MA USA Facility
Feb 2, 2024
These upgrades, including the addition of capacity for both development and commercial spray drying, now position Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.
Catalent Commits to Reducing Greenhouse Gas Emissions by 2030
Jan 25, 2024
The company also committed to engaging with its suppliers such that 70% of their emissions will have reduction goals aligned with science-based targets by the end of fiscal 2028.
Catalent Appoints David McErlane as Biologics Segment Leader
Sep 18, 2023
Mr. McErlane will lead all of Catalent’s Biologics businesses and global service offerings – including development, drug substance manufacturing, drug product fill-and-finish, cell and gene therapy, and analytical services.
American Association of Pharmaceutical Scientists Conference 2024 PharmSci 360
Date: October 21-23, 2024
SupplySide West 2024
Date: October 30-31, 2024
Bio Europe Fall
Date: November 4-6, 2024
World ADC San Diego
Date: November 4-7, 2024
PEGS Europe
Date: November 5-7, 2024
RESCON USA Summit 2024
Date: November 14-15, 2024
CHINATRIALS 16
Date: November 11-13, 2024
9th Annual Clinical Trial Supply East Asia 2024
Date: December 3-4, 2024
Drug Delivery to the Lungs 2024
Date: December 11-13, 2024